Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: Cohort study and literature review

Journal of Pathology

Volumn 222, Issue 4, 2010, Pages 350-366

  Nosho, Katsuhiko ^a   Baba, Yoshifumi ^a   Tanaka, Noriko ^a,b   Shima, Kaori ^a   Hayashi, Marika ^a   Meyerhardt, Jeffrey A ^a   Giovannucci, Edward ^b,c   Dranoff, Glenn ^a,d   Fuchs, Charles S ^a,c   Ogino, Shuji ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Colon cancer; Epigenetics; Immunity; Immunology; Mismatch repair; Reaction; Therapeutic target

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CD3 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; FLUOROURACIL; K RAS PROTEIN; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL DENSITY; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE; T LYMPHOCYTE SUBPOPULATION; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE;

AGED; ANTIGENS, CD45; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA, NEOPLASM; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; T-LYMPHOCYTE SUBSETS; TUMOR MARKERS, BIOLOGICAL;

EID: 78349277576     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2774     Document Type: Article

References (71)

1. Naito Y, Saito K, Shiiba K, et al., CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58: 3491-3494.
2. Guidoboni M, Gafa R, Viel A, et al., Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol 2001; 159: 297-304.
3. Oberg A, Samii S, Stenling R, et al., Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors. Int J Colorectal Dis 2002; 17: 25-29.
4. Petty JK, He K, Corless CL, et al., Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am J Surg 2002; 183: 512-518.
5. Diederichsen AC, Hjelmborg JB, Christensen PB, et al., Prognostic value of the CD4 + /CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 2003; 52: 423-428.
6. Funada Y, Noguchi T, Kikuchi R, et al., Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep 2003; 10: 309-313.
7. Prall F, Duhrkop T, Weirich V, et al., Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004; 35: 808-816.
8. Menon AG, Janssen-van Rhijn CM, Morreau H, et al., Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 2004; 84: 493-501.
9. Chiba T, Ohtani H, Mizoi T, et al., Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer 2004; 91: 1711-1717.
10. Pages F, Berger A, Camus M, et al., Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-2666.
11. Baeten CI, Castermans K, Hillen HF, et al., Proliferating endothelial cells and leukocyte infiltration as prognostic markers in colorectal cancer. Clin Gastroenterol Hepatol 2006; 4: 1351-1357.
12. Galon J, Costes A, Sanchez-Cabo F, et al., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964.
13. Zlobec I, Minoo P, Baumhoer D, et al., Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer 2008; 112: 495-502.
14. Zlobec I, Baker K, Terracciano L, et al., Two-marker protein profile predicts poor prognosis in patients with early rectal cancer. Br J Cancer 2008; 99: 1712-1717.
15. Sinicrope FA, Rego RL, Ansell SM, et al., Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009; 137: 1270-1279.
16. Laghi L, Bianchi P, Miranda E, et al., CD3+ cells at the invasive margin of deeply invading (pT3"T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 2009; 10: 877-884.
17. Frey DM, Droeser RA, Viehl CT, et al., High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 2009; 126: 2635-2643.
18. Salama P, Phillips M, Grieu F, et al., Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27: 186-192.
19. Pages F, Kirilovsky A, Mlecnik B, et al., In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27: 5944-5951.
20. Deschoolmeester V, Baay M, Van Marck E, et al., Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol 2010; 11: 19.
21. Suzuki H, Chikazawa N, Tasaka T, et al., Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol Immunother 2010; 59: 653-661.
22. Correale P, Rotundo MS, Del Vecchio MT, et al., Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 2010; 33: 435-441.
23. Lee WS, Park S, Lee WY, et al., Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. Cancer 2010.
24. Schwitalle Y, Kloor M, Eiermann S, et al., Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 2008; 134: 988-997.
25. Zou W,. Regulatory T cells, tumour immunity and immunotherapy. Nature Rev Immunol 2006; 6: 295-307.
26. Speetjens FM, Lauwen MM, Franken KL, et al., Prediction of the immunogenic potential of frameshift-mutated antigens in microsatellite instable cancer. Int J Cancer 2008; 123: 838-845.
27. Curiel TJ,. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117: 1167-1174.
28. Disis ML, Bernhard H, Jaffee EM,. Use of tumour-responsive T cells as cancer treatment. Lancet 2009; 373: 673-683.
29. Alexander J, Watanabe T, Wu TT, et al., Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 2001; 158: 527-535.
30. Shia J, Ellis NA, Paty PB, et al., Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol 2003; 27: 1407-1417.
31. Jenkins MA, Hayashi S, O'Shea AM, et al., Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 2007; 133: 48-56.
32. Ogino S, Nosho K, Irahara N, et al., Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 2009; 15: 6412-6420.
33. Tougeron D, Fauquembergue E, Rouquette A, et al., Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod Pathol 2009; 22: 1186-1195.
34. Popat S, Hubner R, Houlston RS,. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-618.
35. Ogino S, Nosho K, Kirkner GJ, et al., CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58: 90-96.
36. Samowitz WS, Sweeney C, Herrick J, et al., Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005; 65: 6063-6069.
37. Ogino S, Nosho K, Kirkner GJ, et al., PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009; 27: 1477-1484.
38. Ogino S, Nosho K, Kirkner GJ, et al., A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 2008; 100: 1734-1738.
39. Chan AT, Ogino S, Fuchs CS,. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007; 356: 2131-2142.
40. Ogino S, Kawasaki T, Brahmandam M, et al., Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005; 7: 413-421.
41. Ogino S, Kawasaki T, Kirkner GJ, et al., CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 2006; 8: 582-588.
42. Nosho K, Kawasaki T, Ohnishi M, et al., PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008; 10: 534-541.
43. Ogino S, Brahmandam M, Cantor M, et al., Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 2006; 19: 59-68.
44. Ogino S, Kawasaki T, Brahmandam M, et al., Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006; 8: 209-217.
45. Ogino S, Cantor M, Kawasaki T, et al., CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006; 55: 1000-1006. (Pubitemid 43962613)
46. Weisenberger DJ, Siegmund KD, Campan M, et al., CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nature Genet 2006; 38: 787-793.
47. Ogino S, Kawasaki T, Kirkner GJ, et al., Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 2007; 9: 305-314.
48. Ogino S, Kawasaki T, Nosho K, et al., LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer 2008; 122: 2767-2773. (Pubitemid 351631379)
49. Irahara N, Nosho K, Baba Y, et al., Precision of Pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. J Mol Diagn 2010; 12: 177-183.
50. Ogino S, Brahmandam M, Kawasaki T, et al., Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia 2006; 8: 458-464.
51. Jehan Z, Bavi P, Sultana M, et al., Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer. J Pathol 2009; 219: 337-346.
52. Abubaker J, Bavi P, Al-Haqawi W, et al., Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol 2009; 219: 435-445.
53. Poulogiannis G, Ichimura K, Hamoudi RA, et al., Prognostic relevance of DNA copy number changes in colorectal cancer. J Pathol 2010; 220: 338-347.
54. Webster JA, Beck AH, Sharma M, et al., Variations in stromal signatures in breast and colorectal cancer metastases. J Pathol 2010; 222: 158-165.
55. Baffa R, Fassan M, Volinia S, et al., MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009; 219: 214-221.
56. Horst D, Scheel SK, Liebmann S, et al., The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 2009; 219: 427-434.
57. Fontenot JD, Gavin MA, Rudensky AY,. Foxp3 programs the development and function of CD4 + CD25+ regulatory T cells. Nature Immunol 2003; 4: 330-336.
58. Hori S, Nomura T, Sakaguchi S,. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
59. Michel S, Benner A, Tariverdian M, et al., High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability. Br J Cancer 2008; 99: 1867-1873.
60. Chaput N, Louafi S, Bardier A, et al., Identification of CD8 + CD25 + Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 2009; 58: 520-529.
61. Le Gouvello S, Bastuji-Garin S, Aloulou N, et al., High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008; 57: 772-779.
62. Blatner NR, Bonertz A, Beckhove P, et al., In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci U S A 2010; 107: 6430-6435.
63. Sinicrope FA, Sargent DJ,. Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 2009; 21: 369-373.
64. Boland CR, Goel A,. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138: 2073-2087.
65. Martin SA, Hewish M, Lord CJ, et al., Genomic instability and the selection of treatments for cancer. J Pathol 2010; 220: 281-289.
66. Ferreira AM, Westers H, Sousa S, et al., Mononucleotide precedes dinucleotide repeat instability during colorectal tumour development in Lynch syndrome patients. J Pathol 2009; 219: 96-102.
67. Kang MR, Kim MS, Oh JE, et al., Frameshift mutations of autophagy-related genes ATG2B, ATG5, ATG9B and ATG12 in gastric and colorectal cancers with microsatellite instability. J Pathol 2009; 217: 702-706.
68. Sargent DJ, Marsoni S, Monges G, et al., Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-3226.
69. Kim GP, Colangelo LH, Wieand HS, et al., Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute"National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007; 25: 767-772.
70. Matsuzaki K, Deng G, Tanaka H, et al., The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin Cancer Res 2005; 11: 8564-8569.
71. Mlecnik B, Tosolini M, Charoentong P, et al., Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010; 138: 1429-1440.